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Abstract
Background: Adequate sedation is crucial to the management of children requiring assisted ventilation on Paediatric
Intensive Care Units (PICU). The evidence-base of randomised controlled trials (RCTs) in this area is small and a trial was
planned to compare midazolam and clonidine, two sedatives widely used within PICUs neither of which being licensed for
that use. The application to obtain a Clinical Trials Authorisation from the Medicines and Healthcare products Regulatory
Agency (MHRA) required a dossier summarising the safety profiles of each drug and the pharmacovigilance plan for the trial
needed to be determined by this information. A systematic review was undertaken to identify reports relating to the safety
of each drug.
Methodology/Principal Findings: The Summary of Product Characteristics (SmPC) were obtained for each sedative. The
MHRA were requested to provide reports relating to the use of each drug as a sedative in children under the age of 16.
Medline was searched to identify RCTs, controlled clinical trials, observational studies, case reports and series. 288 abstracts
were identified for midazolam and 16 for clonidine with full texts obtained for 80 and 6 articles respectively. Thirty-three
studies provided data for midazolam and two for clonidine. The majority of data has come from observational studies and
case reports. The MHRA provided details of 10 and 3 reports of suspected adverse drug reactions.
Conclusions/Significance: No adverse reactions were identified in addition to those specified within the SmPC for the
licensed use of the drugs. Based on this information and the wide spread use of both sedatives in routine practice the
pharmacovigilance plan was restricted to adverse reactions. The Clinical Trials Authorisation was granted based on the data
presented in the SmPC and the pharmacovigilance plan within the clinical trial protocol restricting collection and reporting
to adverse reactions.
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Introduction
Adequate sedation is crucial to the management of children
requiring assisted ventilation on the Paediatric Intensive Care Unit
(PICU). The level of sedation of post-operative infants has been
shown to impact on subsequent morbidity, and even mortality
[1,2,3]. Most critically ill children will require potent analgesic and
sedative drugs to facilitate artificial ventilation, alleviate pain,
prevent discomfort from procedures, and to prevent distress from
the presence of unfamiliar personnel and from the high level of
background noise, which can disturb natural sleeping patterns [4].
However, while under-sedation can result in significant morbidity,
over- sedation can also be associated with distressing or dangerous
adverse effects, which may be difficult to assess in critically ill
children [5]. The SLEEPS trial (www.controlled-trials.com/
ISRCTN02639863), a prospective multi-centre randomised, dou-
ble-blind, equivalence study was designed to compare clonidine
and midazolam as intravenous sedative agents in critically ill
children requiring mechanical ventilation.
Midazolam, a benzodiazepine derivative, is the most commonly
used sedative in critically ill children, both in the UK and abroad
[6]. For sedation of the critically ill child it is usually given in
combination with an opioid by intravenous infusion at doses
between 50–300 micrograms/kg/hr [7]. It can also be adminis-
tered via subcutaneous infusion, or via intravenous bolus. Acute
effects of midazolam exposure through continuous infusion
include adverse effects of the drug on the cardiovascular system
[8,9], while continuous exposure to midazolam over several days
results in rapid development of tolerance and subsequent
withdrawal phenomena [1].
Clonidine is an a-2 adrenergic agonist which has antihyperten-
sive, analgesic and sedative effects. In recent years, the drug has
become more frequently used as a sedative in critically ill children
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Table 1. Search Strategy.
Database: Ovid MEDLINE(R) ,1950 to August Week 4 2008.
Search Strategy:
1 child$.mp. or child/(1500744)
2 (paediatric$ or pediatr$).mp. (163973)
3 infant/or infan$.mp. (864884)
4 young$.mp. (304417)
5 toddler.mp. (1117)
6 bab$.mp. (54771)
7 child,preschool/(625996)
8 (preschool or pre-school).mp. (627837)
9 adolesc$.mp. or adolescent/(1304128)
10 teenage$.mp. (10507)
11 youth$.mp. (21868)
12 or/1–11 (2734500)
13 (intensive care or critical care).mp. (90585)
14 intensive care units, pediatric.mp. (2630)
15 intensive care units, neonatal.mp. (6648)
16 picu.mp. (929)
17 p*ediatric intensive care.mp. (3149)
18 ‘‘critically ill’’.mp. (16329)
19 ventilated.mp. (17171)
20 ventilat$.mp. (106904)
21 respiration, artificial.mp. (30372)
22 positive pressure respiration.mp. (13060)
23 intermittent positive pressure breathing.mp. (943)
24 intermittent positive pressure ventilation.mp. (2397)
25 (high frequency ventilation or high frequency oscillation).mp. (1912)
26 high frequency positive pressure ventilation.mp. (127)
27 (hfv or hfov).mp. (764)
28 high frequency jet ventilation.mp. (1084)
29 airway pressure release ventilation.mp. (78)
30 aprv {No Related Terms} (56)
31 continuous mandatory ventilation.mp. or continuous mandatory ventilation/(7)
32 cmv.mp. (14725)
33 intermittent mandatory ventilation.mp. (529)
34 (synchron$ intermittent mandatory ventilation or simv).mp. (206)
35 (pressure suppoprt ventilation or psv).mp. (1254)
36 (extracorporeal membrane oxygenation or ecmo or oxygenation, extracorporeal membrane).mp. (4039)
37 or/13–36 (223297)
38 (intravenous or iv).mp. (467655)
39 parenteral.mp. (63557)
40 inject$.mp. (556405)
41 infus$.mp. (224106)
42 (infus$ or infusions, intravenous).mp. (224106)
43 $venous.mp. (139547)
44 or/38–43 (1144844)
45 midazolam.mp. (7964)
46 midazolam hydrochloride.mp. (64)
47 midazolam maleate.mp. (26)
48 (dormicum or flormidal or versed or hypnovel or dormonid).mp. (496)
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and is usually administered with an opioid by intravenous infusion
or orally.
Midazolam and clonidine are used widely within paediatric
intensive care but are not licensed for that use. As the conditions of
use in the clinical trial differed from those licensed, the Clinical
Trials Authorisation application to the Medicines and Healthcare
products Regulatory Agency (MHRA) required that the Summary
of Product Characteristics (SmPC) for its licensed use be
complemented with a summary of relevant data supporting its
use in the proposed clinical trial. The trial aimed to open to
recruitment in 2009 therefore we aimed to include safety data up
to 2008.
Within the application for funding for the SLEEPS trial the
conclusions from a systematic review [10] were used to justify the
need for the new trial. The need to use systematic reviews to avoid
unnecessary new research is clear but research conducted on using
systematic reviews in the design and planning of a new trial have
indicated that their potential is not being optimised [11,12,13,14].
The aim of this paper is to describe the systematic review of
safety data included within the Clinical Trials Authorisation
application associated with the continuous infusion of midazolam
or clonidine as sedation for neonates, infants and older children
requiring mechanical ventilation and to illustrate how this
informed the pharmacovigilance plan for the SLEEPS trial.
Methods
All authors contributed to and agreed the protocol. Due to the
variety of study designs, anticipated lack of direct comparisons,
and required focus on safety profiles of each drug individually we
did not plan to combine results within a meta-analysis or test for
publication bias.
Criteria for considering studies for the review
We included Randomised Controlled Trials (RCTs), Controlled
Clinical Trials (CCTs), observational studies and case reports or
case series.
We included only studies assessing the safety of continuous
intravenous infusion of midazolam or clonidine when used as
sedation for mechanically ventilated children under the age of
eighteen years. For the literature search the age limit was set to
allow variability in definition of paediatric. Because this review
targeted safety, we included all studies which described the active
or passive monitoring of adverse effects in the methods and/or the
absence or presence of adverse effects in the results. We included
studies administering midazolam or clonidine either on their own
or with a concomitant opioid, reflecting routine clinical practice.
We excluded studies assessing the use of midazolam or clonidine
via any route other than a continuous intravenous infusion. We
excluded studies assessing the use of midazolam as sedation for
procedures, or as an anticonvulsant.
Identification of studies
Prior to conducting the literature search to our knowledge there
were no relevant published systematic reviews for clonidine and
four relevant published systematic reviews [1,10,15,16] for
midazolam. Of these reviews, two related only to the use of
midazolam in neonates [10,15] and two were restricted to
withdrawal symptoms [1,16]. The Cochrane review assessing
intravenous midazolam in neonates had been updated in 2002
[10].
MEDLINE was searched in September 2008. The search
strategy is provided in Table 1. Two reviewers (IS and CS)
independently screened each abstract identified and any queries
were discussed with AW. Full texts of potentially eligible studies
were obtained and their references screened to identify any
additional eligible studies.
Authors of studies that did not report but may have collected
relevant data were not contacted due to time constraints to submit
the CTA application. An assessment was made about the
likelihood of outcome reporting bias within those studies [17].
For studies that included data for adults and children, authors
were contacted to obtain data for children alone.
The Summary of Product Characteristics (SmPC) were
obtained (midazolam from F.Hoffmann-La Roche Ltd as mid-
azolam was originally licensed by this company; clonidine from
Boehringer Ingelheim UK sole UK manufacturer).
Information was requested from the MHRA under the Freedom
of Information Act regarding reports of midazolam and clonidine
being used as a sedative in children. The age limit was set to be 16
years, the upper age limit planned for the SLEEPS trial.
Data extraction
Data extraction was conducted by IS, CS, and CG. All
extracted data were cross checked:
Table 1. Cont.
Database: Ovid MEDLINE(R) ,1950 to August Week 4 2008.
Search Strategy:
49 benzodiazepine.mp. or benzo$/(15817)
50 or/45–49 (22992)
51 (clonidine dihydrochloride or clonidine hydrochloride or clonidine monohydrobromide or clonidine monohydrochloride).mp. (200)
52 (clofelin or clopheline or dixarit or gemiton or hemiton or catapres or catapres*an or clophazolin or colfenil or isoglaucon or klofelin or klonefil or m-5041t or st-
155).mp. (464)
53 (clonidine or clonidin$).mp. (15383)
54 or/51–53 (15506)
55 37 and 44 and 12 (8661)
56 50 and 55 (288)
57 53 and 55 (16)
doi:10.1371/journal.pone.0051787.t001
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1) Study characteristics (design, age of participants, dose and
duration of midazolam or clonidine therapy, concomitant
sedative or opiate therapy);
2) Any data relating to the safety of these drugs, especially
changes in blood pressure or heart rate on induction or
cessation of midazolam or clonidine, withdrawal signs and
symptoms, and negative effects on other organ function. The
adverse effects were subsequently categorised into those
relating to cardiovascular effects, withdrawal effects, and any
other effects;
Assessment of methodological quality
For each RCT and observational study we evaluated how
rigorously the adverse event data were ascertained by assessing
whether adverse effects were actively or passively monitored. We
also determined how well the methods were described and
whether or not the adverse effects of interest were defined a priori.
We examined each study to see if the authors of the study had
assessed the likelihood that adverse events were related to the use
of medication, in other words whether they were considered to be
Adverse Drug Reactions (ADRs). If an assessment of causality was
made, we examined whether this was done using an existing,
validated tool, such as that described by Naranjo [18]. We also
assessed whether authors distinguished between midazolam or
clonidine and a concomitant medication as being the cause of a
suspected ADR.
In addition, for each RCT we assessed the adequacy of
randomisation, allocation concealment and masking of interven-
tions, and in order to assess the quality of reporting we evaluated
whether all children who had received midazolam or clonidine
were included in the safety analysis. We made no assessment of the
quality of case reports or case series, other than whether or not
causality had been assessed.
Results
Results of the search
The results of the search are provided in Figure 1. Table 2 gives
details of excluded studies for which full texts were obtained
together with descriptions of studies that did not report but may
have collected relevant data.
MIDAZOLAM
Thirty-four studies from 33 publications were eligible for
inclusion and provided usable data
[6,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,-
39,40,41,42,43,44,45,46,47,48,49,50](See Figure 1).
Figure 1. Study identification flow diagram.
doi:10.1371/journal.pone.0051787.g001
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Table 2. Details of excluded studies and included studies without usable data.
Category Study Comments
Midazolam
Adults only Aitkenhead 1989 [58]
Bourgoin 2003 [59]
Cernaianu 1996 [60]
Chamorro 1996 [61]
Costa 1994 [62]
Deo 1994 [63]
Dirksen 1987 [64]
Flogel 1993 [65]
Lee 2007 [66]
Lescot 2007 [67]
Searle 1997 [68]
Sinclair 1988 [69]
Stewart 1999 [70]
Tanigami 1997 [71]
Used as sedation for a procedure rather
than ventilation
Bitar 2003 [72] This study assesses the use of sedation for plastic surgery procedures rather than
as sedation on PICU
Djurberg 2002 [73] The study assesses anesthesia for procedures rather than sedation for
mechanical ventilation.
Hertzog 1999 [74] This study assesses anesthesia for procedures rather than sedation for
mechanical ventilation
Hickey 1992 [75] Midazolam not administered as a sedative in PICU but for a procedure in this
study
Koroglu 2005 [76] Dexmedetomidine and midazolam were administered for sedation during an
MRI rather than as sedation on PICU
Laussen 1995 [77] Although midazolam infused alongside other medications, it is for a procedure
rather than a continuous infusion
Malagon 2005 [78] Midazolam is used as procedural anaesthesia rather than sedation
Somri 2007 [79] Midazolam administered for a procedure rather than as sedation and children
not ventilated.
Wilson 2003 [80] Midazolam is used as procedural anaesthesia rather than sedation
Yldzdas 2004 [81] Midazolam is used as procedural anaesthesia rather than sedation
Not administered continuously Gruber 2001 [82] Midazolam was infused continuously during surgery but was only bolused once
on PICU
Harte 1997 [8] Midazolam was administered by bolus rather than continuous infusion in this
study
Van Straaten 1992 [9] Midazolam administered as a bolus rather than a continuous infusion
Hartvig 1993 [83] The study assessed the suitability of constant rate infusions of ketamine as a
sedative agent supplemented with intermittent doses of midazolam. Not
administered continuously
Used as anticonvulsant Anand 1992 [3] Midazolam not administered as a sedative but as a treatment for status
epilepticus in this study.
Not ventilated Prins 2005 [84] Patient in the study were not ventilated
Not used De Cosmo 2005 [85] Assesses the role of propofol in Paediatric Intensive Care Unit (PICU) rather than
midazolam.
Walker 2006 [86] Study started after midazolam ceased. This study examined the use of
dexmedetomidine after the failure of the standard regimen of opioids and
benzodiazepines
Review article Aranda 2005 [15] Review article
Ista 2007 [16] Review article
Ng 2003 [10] Review article
Notterman 1997 [87] Review article
Wolf 1994 [5] This is a commentary
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Table 2. Cont.
Category Study Comments
No usable data Al-Samsam 2005 [88] This study examines the impact of environmental factors on PICU on quantity
and architecture of sleep and did not assess the efficacy or safety of midazolam.
11 included patients were intubated, mechanically ventilated, and sedated with
morphine and midazolam infusions.
Likelihood of relevant safety data is low with low risk of outcome reporting bias.
Ambrose 2000 [51] The study assesses the adverse effects of clonidine. Ventilated children were
given a background infusion of midazolam combined with a variable clonidine
infusion. Reports adequacy of sedation and adverse effects on cardiovascular
performance. Study is included within clonidine review but considered no
usable data for midazolam.
Likelihood of relevant safety data is low with low risk of outcome reporting bias.
Buck 2008 [89] This study assesses the efficacy and safety of Dexmedetomidine rather than
midazolam. Dexmedetomidine was started to minimize the use of midazolam
before extubation or in patients who could not tolerate midazolam.
Likelihood of relevant safety data is low with low risk of outcome reporting bias.
DeBerry 2005 [90] The study is a survey of pain and sedation medications in patients on
extracorporeal membrane oxygenation. The survey did not ask questions
relating to efficacy or safety of the drugs used. A 6 point likert scale ranging
from not effective (1) to desired effect(6) was applied. This was a general score
of clinician experience across patients and did not apply to individual patients.
Midazolam was reported to be most effective drug administered.
Likelihood of relevant safety data is low with low risk of outcome reporting bias.
Enomoto 2006 [91] This was a case study involving prolonged use of dexmedetomidine on failure of
midazolam with fentanyl to achieve adequate sedation and did not relate to
adverse effects of midazolam. Study captured data after sedation with
midazolam had ceased but midazolam reintroduced as an anti convulsant.
Likelihood of relevant safety data is low with low risk of outcome reporting bias.
Jin 2007 [92] This paper assesses the use of the COMFORT score. Midazolam was administered
to 5 patients and inconjuction with fentanyl to 26 patients. Data on withdrawal
symptoms were collected but reported for the comparison of use of the comfort
or not rather than by sedatives.
Likelihood of relevant safety is low and risk of outcome reporting bias low as
sedative types were not the focus of the paper.
Kadilak 2004 [93] The study assesses the safety of long-term intubation rather than the safety of
drugs used for sedation by a retrospective 9-year review of children who
required mechanical ventilatory support for at least 7 consecutive days. Of 98
children 76 (78%) were on midazolam infusions. Study aim did not require
measurement of adverse event data.
Likelihood of relevant safety data is low with low risk of outcome reporting bias.
Lugo 1999 [94] The aim of the study was to assess costs in PICU and not to assess the adverse
effects of midazolam. Midazolam infusion was continued until the hourly
midazolam requirement was stable for at least 24 hrs. Thereafter, patients with a
nasojejunal tube who were likely to require a minimum of three additional days
of continuous sedation were transitioned from intravenous midazolam to
enterally administered lorazepam.
Likelihood of relevant safety data is low with low risk of outcome reporting bias.
Playfor 2000 [95] This study did not assess the adverse effects of midazolam, it assessed the
quality of sedation with continuous intravenous midazolam and morphine with
additional oral sedation using chloral hydrate and antihistamines.
Likelihood of relevant safety data is low with low risk of outcome reporting bias.
Rigby-Jones 2007 [96] This study aimed to determine the pharmacokinetics of remifentanil in children
requiring ventilation after cardiac surgery. Ventilated children were sedated with
a fixed rate infusion of midazolam and a remifentanil infusion.
Likelihood of relevant safety data is low with low risk of outcome reporting bias.
Saha 2006 [97] The retrospective study aimed to describe which drugs were being used during
transfer of critically ill children by retrieval teams.
Likelihood of relevant safety data is low with low risk of outcome reporting bias.
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The MHRA provided details of 10 reports of suspected ADRs.
CLONIDINE
Two studies from two publications were eligible for inclusion
and provided usable data. [51,52]
The MHRA provided details of three reports of suspected
ADRs.
Characteristics of included studies
Summary details of eligible studies which did not report
measuring adverse events are provided in Table 2.
RCTs and CCTs
No RCTs were identified for clonidine. Seven RCTs were
identified for midazolam [19,20,21,22,23,24,25], of which 5 were
set on Neonatal Intensive Care Units [19,20,22,23,25], and two on
Paediatric Intensive Care Units [21,24]. In all but two of the
studies [19,20] patients received midazolam and concomitant
opiates, either as continuous infusion or on an intermittent basis.
Table S1 describes the study characteristics.
One CCT of clonidine set on a Paediatric Intensive Care Unit
was identified [51] and is summarised in Table S2.
Observational studies
Seventeen cohort studies, 13 prospective
[6,26,27,28,29,30,33,34,36,37,39,40,50] and four retrospective
[31,32,35,38], were identified for midazolam. One study was
based on a NICU [36] and the others were based on PICU. In all
but three of these studies [32,34,37] midazolam was administered
in conjunction with opiates and/or other sedative drugs. The
characteristics are summarised in Table S1.
No observational studies were identified for clonidine.
Case series and case reports
Six case series [44,45,47,48,49] and 4 single case reports
[41,42,43,46] were identified for midazolam. Only two of the
children described in all the case reports received midazolam
without concomitant opiate sedative therapy [47,48]. See
Table S3.
One case report [52] was identified for clonidine and is
described in Table S2. This case was reported as clonidine was
being used for a new indication.
Information received from the MHRA
Five of the ten midazolam cases stated the duration of treatment
which ranged from one day to 280 days but the information is
Table 2. Cont.
Category Study Comments
Schmidt 2006 [98] The study prospectively matched pairs of mechanically ventilated neonates
under total parenteral nutrition and midazolam sedation. The aim was to
evaluate fentanyl side effects on the neonatal bladder. All 40 patients received
midazolam then one group received continuous fentanyl infusions aswell with
the other group serving as controls.
Reported use of the COMFOPRT and Hartwig scores indicates measurement of
efficacy. Paper reports potential gastrointestinal side effects. Likelihood of
relevant data for efficacy and safety is high but risk of outcome reporting bias
low as use of fentanyl on the gall bladder and gastrointestinal side effects were
aim of the paper.
Vernon 2000 [99] This study assessed the effects of neuromuscular blockade drugs on oxygen
consumption and energy expenditure. All patients were sedated using
continuous infusions of midazolam and/or fentanyl.
Likelihood of relevant safety data is low with low risk of outcome reporting bias.
Adults and children and data could not be
extract for children separately
Prause 2000 [100] Although children were included in this study, they were not analysed as a
separate group therefore we are cannot determine if any adverse effects
occurred in children. The authors were contacted to obtain paediatric specific
data. No response received.
Shelly 1991 [101] Although children were included in this study, they were not analysed as a
separate group therefore we are cannot determine if any adverse effects
occurred in children. The authors were contacted to obtain paediatric specific
data. No response received.
Clonidine
Administered orally Artman 1983 [102] Clonidine was administered orally rather than intravenously
Tanaka 1995 [103] Clonidine was administered orally rather than intravenously
Adults and children and data could not be
extract for children separately
Prause 2000 [100] Although children were included in this study, they were not analysed as a
separate group therefore we are cannot determine if any adverse effects
occurred in children. The authors were contacted to obtain paediatric specific
data. No response received.
No usable data Jenkins 2007 [6] The aim of this study was to investigate the current practice of sedation,
analgesia, and neuromuscular blockade in critically ill children on paediatric
intensive care units. The study is included in the midazolam review but excluded
for clonidine. It reports 12 patients received i.v. clonidine, and it is likely that
withdrawal symptoms were recorded but not reported due to the small size of
the clonidine sample. The paper reports on the use of clonidine to treat
withdrawal symptoms.
doi:10.1371/journal.pone.0051787.t002
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unclear and suggests midazolam may have been administered as a
bolus rather than a continuous infusion for some or all of the cases.
In four of the cases, concomitant medications were administered
alongside midazolam.
The following suspected adverse drug reactions were reported:
N two convulsions,
N two myoclonus,
N one tremor and dyskinesia,
N one hypoxia,
N one psychomotor, withdrawal, confusional state and halluci-
nation,
N one withdrawal and dystonia,
N one reported asthenia, muscle disorder and myoglobinuria and
N one hepatic failure.
Three reports were received for clonidine. The duration of
treatment was 1098 for the first case and one day for the following
two cases. The infusion rate was unknown for the first case and
1 mcg/kg/hour and 0.7 ug/mg/hour in the other two cases. In
one of the three cases, clonidine was administered with a
concomitant muscle relaxant.
The following suspected adverse drug reactions were reported:
N one hypertension,
N one hypoventilation
N one cardiac arrest and bradycardia.
The value of the data provided by the MHRA is limited as we
do not have any information regarding the specific age groups
involved, we do not know how many, if any, children were
ventilated, and we do not know what duration this data has been
collected over.
Methodological assessment of the studies
Risk of bias in RCTs. Table S4 provides details of the risk of
bias assessment for each RCT. In summary across RCTs:
N methods of sequence generation
N adequate [20,21,22]),
N unclear [19,20,22,23,25].
N allocation concealment
N adequate [22,23,24,25]
N Unclear (15, 16, 17).
N Masking
N Adequate [19,20,22,23,25]
N Unclear [21]
N Inadequate [24] and judged to be at high risk of bias
Quality of adverse effect monitoring
Table S4 provides details of the quality of adverse effect
monitoring for each study with a summary across studies below.
Cardiovascular
Five RCTs actively monitored cardiovascular adverse effects of
midazolam [19,20,21,22,25]. Of these two described their
methods for monitoring haemodynamic parameters adequately
[19,25]. One study defined haemodynamic parameters a priori in
physiological terms [19] and 2 defined hypotension in terms of
whether patients required inotropic or volume support [22,25].
Three of the studies reported all cardiovascular effects numerically
by treatment group [19,21,25]. In one study [21] all patients who
received midazolam were included in the safety analysis for
cardiovascular adverse effects, in one study not all patients were
included [19] and in the remaining studies this information was
unclear.
Four prospective cohort studies actively monitored for cardio-
vascular adverse effects of midazolam, and the methods are clearly
described [26,33,40,50]. Of these, one [26] clearly defined
tachycardia a priori but the other authors did not define abnormal
haemodynamic parameters a priori.
Two retrospective studies assessed cardiovascular adverse events
for midazolam, but it is neither clear how rigorously these were
recorded in the medical case notes, nor how thoroughly they were
sought by the investigators [35,36]. A further two cohort studies,
one prospective [30] and one retrospective [37], report on
cardiovascular adverse events for midazolam but it is unclear
whether these were monitored by active surveillance.
The CCT [51] actively monitored cardiovascular adverse effects
of clonidine and described methods for haemodynamic assessment
clearly. The study reported all cardiovascular effects numerically
by treatment group but excluded two patients from one of the
treatment groups as there was a failure to maintain adequate
sedation.
Withdrawal
Of the 7 RCTs only 2 continued after the cessation of
midazolam [23,24] but did not actively monitor infants for signs of
withdrawal. One [24] did not specify monitoring patients for signs
of withdrawal, but did monitor for abnormal behaviour following
cessation of the drug.
Five [6,26,27,28,34] prospective cohort studies actively moni-
tored signs of withdrawal following cessation of midazolam. The
methods used were clearly described, and three studies clearly
defined the symptoms which would be considered suggestive of
withdrawal [26,28,34].
Two other prospective cohort studies [29,30] monitored for
signs of withdrawal and three other studies [31,37,38] retrospec-
tively assessed medical case notes for signs of withdrawal, but the
methods were are not clearly described, and in the case of the
retrospective studies it is unclear how thoroughly signs of
withdrawal were documented in the notes in the first instance.
The identified CCT did not actively monitor infants for signs of
withdrawal from clonidine infusion.
Neurological
Three RCTs actively monitored patients for neurological
complications while receiving midazolam [22,24,25]. Of these
only one study [24] described the methods used adequately, and
this study was also the only one to define abnormal neurological
findings a priori, describe neurological adverse effects numerically
by treatment group, and specifically state that all patients who
received midazolam were included in the safety analysis for
neurological adverse effects.
Many studies that evaluated the risks of suffering withdrawal
after midazolam infusions also assessed neurological symptoms as
part of this assessment. Only two [35,38] report on children with
neurological symptoms not in the context of weaning or
discontinuation of midazolam. Because these were retrospective
case note reviews it is unclear how well the clinical data were
recorded in the first instance. One neonatal study [23] assessed
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neurological outcomes in preterm infants, but it would appear that
this assessment was related to the clinical efficacy of sedative
regimes rather than direct consequences of using midazolam
infusion.
The identified CCT [51] did not actively monitor patients for
neurological complications while receiving clonidine infusion.
Prolonged sedation
One RCT [24] and two prospective cohort studies [34,50]
actively monitored children for prolonged sedation after discon-
tinuation of midazolam infusion.
Metabolic/endocrine
One cohort study [40] prospectively assessed children receiving
midazolam for altered hypothalamic-pituitary-adrenal axis func-
tion, and the authors clearly describe the cortisol stimulation test
used. One study retrospectively assessed patients for metabolic
acidosis and lipaemia [32]. This was done to assess the safety of
propofol rather than midazolam.
Adverse events
Cardiovascular/respiratory. Two RCTs [19,25] described
some cardiovascular complications in children receiving midazo-
lam infusion. Van Alfen van der velden [19] classed the
cardiovascular complications as an ADR whereas Jacqz-Aigrain
[25] did not attribute causality of the complications to the drug.
One other RCT [20] also described some cardiovascular adverse
effects, but classed them as not clinically significant and ‘transient’.
Arya [22] and Tobias [21] did not observe adverse cardiovascular
effects associated with midazolam infusion.
Van Alfen van der velden [19] described a decrease in cerebral
blood flow after starting midazolam. Hypotension occurred in 7/
21 preterm neonates who had received midazolam, and two of
these infants required haemodynamic support. Jacqz-Aigrain [25]
compared cardiovascular effects of midazolam compared with
placebo in newborn infants and found that ‘heart rate and blood
pressure were significantly lower in the midazolam group’, a
difference which remained statistically significant until 48 hours.
By day 5 the mean heart rate and blood pressure values were
equal. 8 infants in the midazolam group required haemodynamic
support [25]. The authors of this study did not classify these
cardiovascular events as ADRs.
Three prospective cohort studies [26,33,36] describe some
cardiovascular adverse effects of midazolam. Ista [26] states that
hypotension was observed in ‘‘.13% of assessments’’ during
weaning or after discontinuation of midazolam. Jacqz-Aigrain [36]
describes hypotension in four newborn infants, in three of whom it
occurred immediately after the initial bolus of midazolam, and in
the fourth immediately after receiving a dose of fentanyl [36].
Shekerdemian [33] describes ‘transient’ haemodynamic changes in
children receiving midazolam infusion [33]. One case report [46]
describes a 40 month old child on continuous midazolam and
opiate infusion who ‘‘experienced several episodes of hypotension’’
that required haemodynamic support.
One other case report [42] and two case series [44,48] describe
increase in heart rate and blood pressure associated with
withdrawal from midazolam, rather than during the infusion.
Biswas [43] reports a 6 month old child with investigations
suggestive of myocardial ischaemia associated with tachycardia
and hypertension from ‘Severe Benzodiazepine and Opioid
Withdrawal’.
Of the seven studies that reported cardiovascular adverse
effects, six of the studies appeared to classify the effects as being
related to midazolam whereas one did not [25].
The CCT [51] did not observe any adverse cardiovascular
effects associated with clonidine infusion and stated that ‘‘brady-
cardia and hypotension were not recorded in any patient’’.
The case report [52] stated that ‘‘haemodynamic parameters
were not adversely affected’’ by clonidine infusion.
Withdrawal and behavioural
Withdrawal from midazolam was not monitored or reported in
any of the 7 RCTs.
Six prospective cohort studies report possible withdrawal
symptoms after continuous infusion with midazolam
[6,26,27,28,34] and all were considered to be ADRs. Ista [26]
reports that, in 79 patients who received midazolam infusion as
sedation and were observed a total of 2188 times, over 10% of the
observations suggested some symptom associated with withdrawal.
Jenkins [6] reported that 29/182 infants and children receiving
midazolam suffered from withdrawal symptoms as judged by the
attending clinicians. The symptoms were not described. It is
unclear how many of the 27 children participating in the study of
weaning protocols by Ducharme [27] suffered from withdrawal,
but ‘many’ of the patients had ‘behavioural distress score’ of
greater than zero while weaning from midazolam. Franck [28]
reports that 13/15 patients exhibited some signs of withdrawal
over three or more assessment periods, and the commonest
symptoms were hyperpyrexia, ‘sleeplessness’, diarrhoea, dilated
pupils and tremors. The commonest symptoms were those of
agitation (57/79 patients), inconsolable crying (38/79), motor
disturbance (43/79), sleep disturbance (73/79), and tachypnoea
(72/79). It is unclear how many patients experienced no symptoms
of withdrawal at all, nor how many of the observational periods
were asymptomatic of withdrawal symptoms. Sheridan [30]
reports that one child suffered withdrawal symptoms after
discontinuation of midazolam. These symptoms consisted of
vomiting, tremulousness and sweating. Hughes [34] reports that
8/53 children in their study had ‘abnormal behaviour’ after
discontinuing midazolam therapy. Three patients had visual
hallucinations (one of these also had auditory hallucinations),
three were ‘clearly disorientated’ and two patients did not
recognise their parents, had ‘puppet-like’ movements and ‘laughed
inappropriately’.
Three retrospective cohort studies report possible withdrawal
symptoms. Rosen [37] reported that 1/55 patients developed
visual hallucinations and tremors after discontinuing midazolam
but the authors did not class this as an ADR. Bergman [38]
describes 3 children who, upon discontinuation of midazolam
infusion, developed neurological symptoms. The authors state that
these may have been a ‘‘toxic reaction or withdrawal reaction to
prolonged intravenous infusion of midazolam’’. Fonsmark [31]
reported that 12/38 patients receiving midazolam were retrospec-
tively judged to be suffering from withdrawal symptoms indicating
that the authors suspect the adverse effects are related to the drug.
Four case series and five case reports described symptoms that
were attributed by the authors to benzodiazepine withdrawal. The
symptoms reported included irritability, agitation, restlessness or
inconsolability [42,43,44,46,47,48,49], abnormal movements
(Choreoathetoid or non purposeful [42,46,47], seizures [49],
‘moving limbs vigorously’[44], myoclonic jerks and orofacial
abnormal movements [41]), hallucinations [41,49], grimacing
[44,49], ‘jitteriness’[44,45], clonus [42], disorientation or abnor-
mal communicative skills [41,44,46], blindness [46], abnormal
behaviour [41], hyperactivity and aggression [49] vomiting
[44,48], diarrhoea [43], poor feeding [44], hypertension and
tachycardia [43,44,48], and yawning [43].
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Of the 9 observational studies that reported withdrawal
symptoms, 8 of these attribute the symptoms to the drug whereas
one does not [37]. In addition there were 9 case series/case reports
that reported withdrawal symptoms and all attribute the symptoms
to the drug. None made formal causality assessments but all the
symptoms reported as withdrawal are all expected side effects of
midazolam. No author used methods to distinguish whether
patients were suffering from Benzodiazepine Withdrawal Syn-
drome, or whether their clinical features reflected withdrawal from
another drug.
Neither of the studies monitored or reported withdrawal from
clonidine infusion.
Neurological
In two RCTs no neurological complications were reported
[22,24], and in one RCT [25] a child was withdrawn because of
‘‘major neurological disorders within 24 hours of inclusion, but the
authors do not state that this was due to midazolam. One RCT
[19] did not actively monitor participants for neurological
complications, but reported that 5/11 patients treated with
midazolam developed myoclonus.
Two retrospective cohort studies [35,38] described neurological
complications of midazolam infusion. Bergman [38] describes 3
children who developed abnormal movements after stopping
midazolam (mentioned in section on withdrawal). One child
became irritable and developed ‘‘arching of the back, stiff and
abnormal movements, an inability to swallow, poor visual
following, no social interaction, a stiff posture, and small amplitude
choreic movements of the hands, feet and tongue’’. Another child
developed ‘‘choreoathetotic movements of the head, face, tongue
and extremities’’. The final child developed ‘‘frequent dyskinetic
movements of the mouth’’. The authors state that they suspected
that these adverse effects ‘‘represented either a toxic reaction or a
withdrawal reaction to prolonged intravenous infusion of mid-
azolam’’. Sheridan [35] reported that 2/24 children, upon
extubation, developed persistent disconjugate gaze that lasted 5
days in one patient and 14 days in the other. The authors imply
that they consider this to be an ADR.
Neither of the studies monitored or reported any neurological
complications of clonidine infusion.
Prolonged sedation
One RCT [24] and two prospective cohort studies [34,50]
evaluated ‘prolonged sedation’ after midazolam. Parkinson [24]
did not report any prolonged sedation after discontinuing
midazolam, Hughes [34] reported that 4/53 patients took between
6 hours to 1 week to become fully alert, and Lloyd Thomas [50]
reports that two children suffered from ‘prolonged sedation’,
lasting 3.3 hours and one lasting 20.5 hours.
Endocrine/metabolic
One prospective cohort study (Booker 1986) assessed the effect
of midazolam on the hypothalamic-pituitary-adrenal axis, by
measuring response to synacthen stimulation. The authors
conclude that ‘‘cortical secretion was not inhibited’’ by midazolam
infusion [40].
One retrospective case-control study [32] compared the
incidence of metabolic acidosis and lipaemia in children treated
with midazolam with those treated with propofol. 17/92 patients
on midazolam developed ‘‘clinically significant metabolic acidosis’’
and 1/92 had lipaemic serum. This primary aim of this study was
to assess known side effects of propofol rather than midazolam. No
other studies assessed these side effects in children treated with
midazolam.
Discussion
We have systematically reviewed the adverse effects of
midazolam and clonidine in children, when used for children
requiring sedation while receiving mechanical assisted ventilation
on PICU. To our knowledge this is the most comprehensive
systematic review to date covering a broad range of adverse effects
in all paediatric age groups.
Main findings of the review
The findings of this systematic review suggest that midazolam
infusion may be associated with cardiovascular adverse effects. In
neonates, midazolam has been associated with systemic and
cerebral hypotension [19,25,36]. In older children an association
between midazolam and haemodynamic side effects has also been
suggested [46]. It would appear that discontinuation of midazolam
can cause hypertension and tachycardia, which may be clinically
significant [42,43,44,48]. Discontinuation of midazolam has also
been strongly associated with a variety of clinical features which
could be suggestive of withdrawal. These symptoms can broadly
be categorised as being related to irritability, neurological and
behavioural abnormalities, gastro-intestinal dysfunction and auto-
nomic dysfunction.
[6,26,27,28,31,34,37,38,42,43,44,45,46,47,48,49]. It would also
appear, unsurprisingly, that these problems become more likely in
children receiving higher doses of midazolam over longer periods
[6,31]. It is difficult to accurately estimate the frequency with
which withdrawal symptoms occur, but in the prospective studies
that we identified the reported incidence appears to range from
15% [6,34]to 85%[28].
Midazolam infusion is also associated with neurological side
effects [35,38] and prolonged sedation [34,40].
There are a limited number of studies published regarding the
use of clonidine in all paediatric age groups. The studies we have
reviewed would suggest that clonidine infusion does not have
adverse cardiovascular effects [51,52].
Robustness of this review
The scope of our review was focussed enough to enable us to
concentrate on one specific indication of midazolam and
clonidine, but broad enough for us to feel that we have included
as much information about the side effects of these drugs when
given in this situation as possible. Our review was conducted
according to a predefined protocol, which was designed according
to the guidelines suggested by the Cochrane Adverse Effects
Methods Group [53]. In doing so we feel we have not only
systematically identified all the relevant literature, but also
rigorously appraised it.
Midazolam and clonidine are not only used for sedation on
PICU. Clonidine is also administered orally for preoperative
sedation in the paediatric population. Midazolam can also be
administered as an intravenous bolus, as a subcutaneous infusion,
intranasally or via the buccal route. The sedative properties of
midazolam can be utilised during operative procedures, or for
simple procedures on general paediatric wards, while its anticon-
vulsant properties render it a useful therapy for status epilepticus.
These alternative indications and preparations of midazolam and
clonidine may be associated with adverse effects specific to these
settings and uses and warrant a separate systematic review of
safety. It was felt that the safety of continuous infusion of
midazolam and clonidine as sedation on PICU is a hugely
important and distinct clinical question, which we feel justifies our
exclusion of studies relating to other uses of these drugs.
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Quality of the evidence
The studies we identified varied significantly in quality, and the
data regarding adverse effects that we have identified must be
interpreted in the context of a variety of limiting factors.
Much of the data in our review has come from observational
studies and case reports. This is especially evident with regard to
the paediatric (rather than neonatal) age group. For example, the
only information relating to cardiac side effects during midazolam
in children is from a case report [46]. With regard to the
evaluation of withdrawal symptoms associated with midazolam,
the data are all derived from observational studies in older
children. One of the RCTs [24] we included was not adequately
masked, and as the outcomes measured in this trial were
subjective, this may have biased the results.
None of the studies included in this review used a causality tool
to assess the likelihood that the adverse events identified were
ADRs. However, all the adverse effects that we identified are
already listed in the respective Summary of Product Character-
istics and can therefore be considered ‘‘expected’’.
Consensus guidelines regarding the conduct of clinical trials of
sedation for neonates have been produced, but there is currently
no consensus for the methodology, definitions, or outcomes that
should be used in infants and older children on PICU [54,55]. The
studies we have identified vary in terms of the rigour with which
adverse effects are sought, and the analysis and reporting of the
results. The tools used to evaluate the presence of withdrawal, and
the definitions of what constitutes benzodiazepine withdrawal
itself, also vary between studies. Furthermore, the tools which are
currently available have not been sufficiently validated, and this
may explain the non-uniformity with which they are used in
clinical research [56]. The clinical features of Benzodiazepine
withdrawal are similar to those from opiate withdrawal, stress,
delirium and inadequate pain management, and this already
makes assessment of these symptoms within the context of the
studies we have identified very difficult [5,26]. Until a measure of
withdrawal that has been properly designed and rigorously
evaluated for measures of validity, reliability, responsiveness and
ease of use in clinical and research situations the identification and
quantification of benzodiazepine withdrawal in children will be
compromised.
Implications for pharmacovigilance assessment in the
SLEEPS trial
The decision about whether to collect all adverse event data or
restrict collection should be determined by a risk assessment for
the trial and consider how well established the risk/benefit profile
of the medicines under study are, licensing status of the drugs and
current level of clinical use. [57] The risk assessment for the
SLEEPS trial was also informed by this systematic review which
did not identify any additional safety concerns to those specified
within the existing SmPCs therefore a decision was made to
restrict data collection to adverse reactions. This decision was also
influenced by the administrative burden at sites if research nurses
were requested to collect all adverse events occurring in critically
ill children, and that the volume of events unrelated to treatment
would reduce the focus of pharmacovigilance monitoring.
However given the low levels of data relating to clonidine we
aimed to collect all adverse reactions rather than restrict to serious
adverse reactions. In addition given the relatively sparse data on
withdrawal symptoms this was added as a secondary outcome of
the trial. This was considered particularly important as younger
children may require substantially higher doses (mg/kg) than older
children and adolescents and the risk of dependence is known to
increase with dose and duration of sedation. Specifying withdrawal
as an outcome meant that symptoms would be actively assessed in
all children. The pharmacovigilance plan was specified within the
trial protocol and reviewed by the MHRA during the CTA
assessment.
In conclusion, our review has highlighted significant and
potentially serious side effects associated when midazolam is
administered according to usual PICU practice. Because children
on PICU are already critically ill, side effects due to midazolam
can easily be over-looked due to other pressing issues with their
care or can be attributed to other causes of cardiovascular or
neurological disturbance associated with their disease or treat-
ment. This may explain the relatively low number of reports held
by the MHRA. It is therefore crucial that clinicians are aware of
the potential iatrogenic risks of midazolam and consider this drug
as a potential cause of adverse events and actively report suspected
reactions to the MHRA. Conversely the evidence regarding the
safety of clonidine infusions as sedation for ventilated children on
PICU is sparse. Critically ill children need adequate sedation to
protect these vulnerable children from the known adverse effects of
withholding sedation during their PICU admission. Identifying the
specific features of drug side effects, finding an optimum drug
therapy at the appropriate dose and achieving the right balance of
sedation is a major challenge. Finding this balance requires high
quality clinical research to improve what is currently a poor
evidence-base regarding safety and optimal delivery.
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